-
1
المؤلفون: Thomas Powles, Srikala S. Sridhar, Yohann Loriot, Joaquim Bellmunt, Xinmeng Jasmine Mu, Keith A. Ching, Jie Pu, Cora N. Sternberg, Daniel P. Petrylak, Rosa Tambaro, Louis M. Dourthe, Carlos Alvarez-Fernandez, Maureen Aarts, Alessandra di Pietro, Petros Grivas, Craig B. Davis
المساهمون: RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9)
المصدر: Nature Medicine, 27(12), 2200-2211. Nature Publishing Group
مصطلحات موضوعية: CLINICAL BENEFIT, MULTICENTER, DNA-DAMAGE RESPONSE, General Medicine, Antibodies, Monoclonal, Humanized, OPEN-LABEL, CANCER, General Biochemistry, Genetics and Molecular Biology, Antineoplastic Agents, Immunological, Urinary Bladder Neoplasms, TUMOR, PD-1/PD-L1 BLOCKADE, Mutation, Marcadors bioquímics, Biomarkers, Tumor, REGULARIZATION, Humans, IMMUNOTHERAPY, Bufeta--Càncer--Tractament, PEMBROLIZUMAB, Càncer
وصف الملف: application/pdf